Ghent University
BactoRelief
Confidential
Frequent
Cough
Respiratory
Infections
Shortness of
Breath
General
Fatigue
02
Bronchiectasis
Ghent University
BactoRelief
The problem
Live Biotherapeutic Product (LBP)
- Defined consortium of "natural" live bacteria
03
Ghent University
BactoRelief
The Solution
- Synergism compared to individual species
- Prevent or treat pathological inflammation
Ghent University
BactoRelief
04
Formulation containing LBP
Freeze-drying
Product
Chronic lung
inflammation ↓
Nebulization
Saline
The Solution
Ghent University
BactoRelief
05
High unmet clinical need
1,163,411 patients in US, UK, Germany
Projected market growth
(965,8 million USD by 2031)
Market opportunity of BactoRelief
Ghent University
BactoRelief
Competitive landscape and USP
Other LBPs
for lung diseases
4 Pipeline LBPs (preclinical)
Disease: Asthma, COPD, IPF, ARDS, bronchiectasis
Product: Lactobacillus-based
Delivery: Inhalation
1 Pipeline LBPs (preclinical)
Disease: Pneumonia
Product: Lactobacillus/Mycobacterium-based
Delivery: Inhalation
06
Differentiator
Reclaiming health with natural bacteria
Ghent University
BactoRelief
Competitive landscape and USP
Other LBPs
for lung diseases
4 Pipeline LBPs (preclinical)
Disease: Asthma, COPD, IPF, ARDS, bronchiectasis
Product: Lactobacillus-based
Delivery: Inhalation
1 Pipeline LBPs (preclinical)
Disease: Pneumonia
Product: Lactobacillus/Mycobacterium-based
Delivery: Inhalation
07
Approved LBPs
Treatment recurrent C. difficile infections (gut)
Other anti-inflammatory drugs
Phase 3 trial successful (28/5/24)
Disease: Bronchiectasis
Product: DPP1 inhibitor
Delivery: oral
Brensocatib
Ghent University
BactoRelief
Status of technology
08
% inflammation
Ghent University
BactoRelief
Status of technology
09
Ghent University
BactoRelief
Status of technology
10
Ghent University
BactoRelief
Status of technology
11
Freeze-dried formulation
with cryoprotectans
Long-term storage
(up to 1 year)
Nebulization
Ghent University
BactoRelief
IP
12
- “Bacterial compositions with anti-inflammatory activity”
- LBP based on combinations of at least two species of anti-inflammatory genus
- Applications for diverse inflammatory diseases
- National phase EPO and USPTO
Ghent University
BactoRelief
Roadmap
13
IOF Stepstone
Seed Funding (6-7M)
Series a Funding
Lead LBP to candidate LBP
Candidate LBP to first-in-human
Investment
ready
IND
ready
Start
first-in-human trials
BactoRelief
Launch of
Jan
2025
Jan
2027
Jan
2029
Ghent University
BactoRelief
Team
14
Principal investigators
Lead scientist
Entrepreneur in residence
Scientist
Technician
Prof. Aurélie Crabbé
Prof. Tom Coenye
Apr. Axelle Van Daele
(PhD student)
UGent valorisation officers
Dr. Eline Soetens
Dr. Gudrun Antoons
Advisory board
Start May 2025
To be recruited 2025
To be recruited 2025
To be recruited 2025
-
What data (or other aspects of the spin-off project) do you consider critical to be "investor-ready" to enable launch of BactoRelief?
-
Our current 2-year plan to further de-risk BactoRelief (with UGent IOF funding):
-
Dose-response studies in small animal model (safety and efficacy)
-
Formulation and delivery
-
Regulation and business development
-
-
-
What are your thoughts about the spin-off team, and would you have suggestions for key expertise in the advisory board?
-
From an investor’s perspective, how important is it that the scientific founding team has a substantiated understanding of the investment amount needed for the next funding rounds? How much does this influence your perception of the team’s business readiness?
Questions
Ghent University
BactoRelief
15